226 related articles for article (PubMed ID: 26324105)
1. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
Kostev K; Dippel FW; Rathmann W
Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
[TBL] [Abstract][Full Text] [Related]
2. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
3. Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.
Anderten H; Dippel FW; Kostev K
J Diabetes Sci Technol; 2015 May; 9(3):644-50. PubMed ID: 25573957
[TBL] [Abstract][Full Text] [Related]
4. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
5. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.
Rys P; Wojciechowski P; Rogoz-Sitek A; Niesyczyński G; Lis J; Syta A; Malecki MT
Acta Diabetol; 2015 Aug; 52(4):649-62. PubMed ID: 25585592
[TBL] [Abstract][Full Text] [Related]
6. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
Odawara M; Kadowaki T; Naito Y
J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
[TBL] [Abstract][Full Text] [Related]
8. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
[TBL] [Abstract][Full Text] [Related]
9. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
10. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
[TBL] [Abstract][Full Text] [Related]
11. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.
Zdarska DJ; Kvapil M; Rusavy Z; Krcma M; Broz J; Krivska B; Kadlecova P
Wien Klin Wochenschr; 2014 Apr; 126(7-8):228-37. PubMed ID: 24563017
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia in patients with type 2 diabetes newly initiated on basal insulin in the US in a community setting: impact on treatment discontinuation and hospitalization.
Dalal MR; Kazemi MR; Ye F
Curr Med Res Opin; 2017 Feb; 33(2):209-214. PubMed ID: 27737571
[TBL] [Abstract][Full Text] [Related]
14. Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin.
Fiesselmann A; Wiesner T; Fleischmann H; Bramlage P
Acta Diabetol; 2016 Oct; 53(5):717-26. PubMed ID: 27093968
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
17. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
Sleeman A; Odom J; Schellinger M
Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
[No Abstract] [Full Text] [Related]
19. Comparison of once-daily glargine insulin with twice-daily NPH/regular insulin for control of hyperglycemia in inpatients after cardiovascular surgery.
Yeldandi RR; Lurie A; Baldwin D
Diabetes Technol Ther; 2006 Dec; 8(6):609-16. PubMed ID: 17109592
[TBL] [Abstract][Full Text] [Related]
20. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
